News

€12m to develop a Crohn’s therapy
Enlarge image

BusinessFrance

€12m to develop a Crohn’s therapy

27.11.2012 - French TxCell closes a third financing round. With €12.4m, the company will bring its T cell-based immunotherapy for Crohn’s disease into Phase III.

TxCell SA is a biotechnology company from Valbonne specialising in T cell-based immunotherapies for the treatment of severe chronic inflammatory diseases. On 26 November, it announced the successful closure of a third financing round for €12.4m. The money largely comes from the InnoBio fund. Managed by CDC Enterprises, the fund accounts for €6m. The remaining amount has been provided by TxCell’s existing shareholders Auriga Partners and Seventure Partners, two venture capital firms firmly rooted in France. Both VCs have a strong background in biotechnology. Auriga also financed lab equipment specialist Cytoo SA from Grenoble, Seventure a biofuel plant in Toulouse .

These additional financial resources will enable TxCell to pursue the development of its lead product candidate, Ovasave®. The antigen-specific Treg cell-based immunotherapy is for the treatment of Crohn’s disease in patients who are refractory to current treatments. Laurent Arthaud, Deputy CEO at CDC Entreprises said: “We are impressed by the innovative therapeutic approach and the encouraging positive clinical data obtained so far by TxCell. The company has a strong and experienced management team in place, and this capital injection will provide the necessary resources to confirm the clinical findings obtained so far and reach the next important development milestone.” To date, TxCell has completed a first in man Phase I/II clinical study that proved tolerability and efficacy of Ovasave®. 

© eurobiotechnews.eu/ml

FundingEU

11.07.2014 Among the seven newly launched Joint Technology Initiatives (JTI) of Horizon2020 are two with deep roots in biotech: IMI is going into its second round while the newly established Bio-based Industries partnership invests in bioeconomy.

Stock marketNetherlandsUKBelgium

10.07.2014 Not one but two biopharma companies are seeking entry into the stock market: After Abzena raised €25m in an IPO earlier this week, Argen-x has followed suit and sold shares worth €40m.

M&AUKIreland

08.07.2014 Abbvie is determined to bring home British rare disease specialist Shire in a merger worth £30.1bn (€37.9bn). So far, Shire has rejected all offers from the US company.

M&ASwitzerland

04.07.2014 Genentech, a member of Swiss Roche Group, is set to acquire US-biotech Seragon Pharmaceuticals Inc. With the move, Genentech will obtain the rights to investigational breast cancer treatments.

M&AFranceGermany

03.07.2014 Nicox S.A. is stretching beyond the European market: The French eye health specialist is set to acquire Aciex Therapeutics Inc., a US-based pharma company with several ophthalmic therapeutics nearing market maturity.

FinanceBelgium

01.07.2014 Belgian antibody specialist Ablynx has raised €41.7m through a private placement of new shares and plans on boosting their range of nanobodies in development.

BioeconomyBelgiumUK

30.06.2014 Building on a £1.2m financing round, Celtic Renewables partners with a Belgian pilot plant to bring its bio-fuel made from whisky production residue to an industrial scale.

ConventionEUUK

25.06.2014 Sun, celebrities and a scandal - the world’s largest biotech convention is getting off to an explosive start in San Diego, California.

InvestmentGermanyNetherlands

24.06.2014 Bayer Healthcare is getting back into gene therapy with a US$252m deal aimed at the development of a haemophilia A treatment.

InvestmentNetherlands

20.06.2014 Tomtom founder Pieter Geelen invests in Dutch biotech Ocello, the company behind a 3D mapping technology used for predicting drug behaviour in patients.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • DIAMYD MEDICAL -B- (S)3.26 SEK5.16%
  • OREXO (S)121.00 SEK4.54%
  • CO.DON (D)2.88 EUR4.35%

FLOP

  • ANTISOMA (UK)1.32 GBP-14.84%
  • XENETIC BIOSCIENCES (UK)6.00 GBP-14.29%
  • EPIGENOMICS (D)3.06 EUR-8.38%

TOP

  • CELLECTIS (F)13.54 EUR112.6%
  • SANTHERA (CH)68.40 CHF107.3%
  • ADDEX (CH)4.40 CHF101.8%

FLOP

  • THROMBOGENICS (B)8.51 EUR-51.5%
  • MERCK KGAA (D)63.98 EUR-50.3%
  • VERONA PHARMA (UK)1.15 GBP-45.2%

TOP

  • SANTHERA (CH)68.40 CHF3009.1%
  • GW PHARMACEUTICALS (UK)439.50 GBP835.1%
  • PAION (D)2.80 EUR324.2%

FLOP

  • CYTOS (CH)0.25 CHF-92.8%
  • EVOCUTIS (UK)0.21 GBP-92.6%
  • THROMBOGENICS (B)8.51 EUR-73.6%

No liability assumed, Date: 13.07.2014